F2 Gel Matrix - a Novel Delivery System for Immune and Gene Vaccinations

  • Published : 2016.07.01


Exploiting the immune system to abolish cancer growth via vaccination is a promising strategy but that is limited by many clinical issues. For DNA vaccines, viral vectors as a delivery system mediate a strong immune response due to their protein structure, which could afflect the cellular uptake of the genetic vector or even induce cytotoxic immune responses against transfected cells. Recently, synthetic DNA delivery systems have been developed and recommended as much easier and simple approaches for DNA delivery compared with viral vectors. These are based on the attraction of the positively charged cationic transfection reagents to negatively charged DNA molecules, which augments the cellular DNA uptake. In fact, there are three major cellular barriers which hinder successful DNA delivery systems: low uptake across the plasma membrane; inadequate release of DNA molecules with limited stability; and lack of nuclear targeting. Recently, a polysaccharide polymer produced by microalgae has been synthesized in a form of polymeric fiber material poly-N-acetyl glucosamine (p-GlcNAc). Due its unique properties, the F2 gel matrix was suggested as an effective delivery system for immune and gene vaccinations.


  1. Bolhassani A, Safaiyan S, Rafati S (2011). Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer, 10, 3.
  2. Cole DJ, Gattoni-Celli S, McClay EF, et al (1997). Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res, 3, 867-73.
  3. Fischer TH, Thatte HS, Nichols TC, et al (2005). Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials, 26, 5433-43.
  4. Kumar SS, Puttaraju HP (2012). Improvised microinjection technique for mosquito vectors. Indian J Med Res, 136, 971-8.
  5. Liu SX, Xia ZS, Zhong,YQ (2014). Gene therapy in pancreatic cancer. World J Gastroenterol, 20, 13343-68.
  6. Luo D, Saltzman WM (2000). Synthetic DNA delivery systems. Nat Biotechnol, 18, 33-7.
  7. Maitre N, Brown JM, Demcheva M, et al (1999). Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res, 5, 1173-82.
  8. Nayerossadat N, Maedeh T, Ali PA (2012). Viral and nonviral delivery systems for gene delivery. Adv Biomed Res, 1, 27.
  9. Patil SD, Rhodes DG, Burgess DJ (2005). DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J, 7, 61-77.
  10. Potter H, Heller R (2011). Transfection by electroporation. Curr Protoc Neurosci Appendix, 1, 1.
  11. Rosenberg SA, Spiess P, Lafreniere R (1986). A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science, 233, 1318-21.
  12. Salem ML, Attia WY, Al-Bolkiny YE, et al (2010b). Using poly-N-acetyl glucosamine gel matrix to deliver IL-12 with antischistosomasis vaccination. J Infect Dev Ctries, 4, 318-28.
  13. Salem ML, Shoukry NM, Zidan, AA (2014a). Vournakis, J., Immunomodulatory effects of IL-12 released from poly-N-acetyl glucosamine gel matrix during schistosomiasis infection. Cytotechnol, 66, 667-75;
  14. Vournakis JN, Demcheva M, Whitson A, Guirca R, Pariser ER (2004). Isolation, purification, and characterization of poly-N-acetyl glucosamine use as a hemostatic agent. J Trauma, 57, 2-6.
  15. Vournakis JN, Demcheva MV (2012). Compositions and methods for nanopolymer-based nucleic acid delivery. Google Patents.
  16. Vournakis JN, Finkielsztein S, Pariser ER, Helton M (1997) Poly-${\beta}$-$1^{\rightarrow}$-4-N-acetylglucosamine. Google Patents: .